BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 38750474)

  • 1. Implications of GCLC in prognosis and immunity of lung adenocarcinoma and multi-omics regulation mechanisms.
    Huang Z; Liang F; Wu J; Huang Z; Li Y; Huang X; Liu Z
    BMC Pulm Med; 2024 May; 24(1):239. PubMed ID: 38750474
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ferroptosis-Related Gene GCLC Is a Novel Prognostic Molecular and Correlates with Immune Infiltrates in Lung Adenocarcinoma.
    Luo L; Zhang Z; Weng Y; Zeng J
    Cells; 2022 Oct; 11(21):. PubMed ID: 36359768
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Signatures of Multi-Omics Reveal Distinct Tumor Immune Microenvironment Contributing to Immunotherapy in Lung Adenocarcinoma.
    Huang Z; Li B; Guo Y; Wu L; Kou F; Yang L
    Front Immunol; 2021; 12():723172. PubMed ID: 34539658
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel ferroptosis-related genes model for prognosis prediction of lung adenocarcinoma.
    Li F; Ge D; Sun SL
    BMC Pulm Med; 2021 Jul; 21(1):229. PubMed ID: 34256754
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A ferroptosis-related gene signature predicts overall survival in patients with lung adenocarcinoma.
    Gao X; Tang M; Tian S; Li J; Liu W
    Future Oncol; 2021 Apr; 17(12):1533-1544. PubMed ID: 33432837
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multi-omics analysis of genomics, epigenomics and transcriptomics for molecular subtypes and core genes for lung adenocarcinoma.
    Zhao Y; Gao Y; Xu X; Zhou J; Wang H
    BMC Cancer; 2021 Mar; 21(1):257. PubMed ID: 33750346
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel ferroptosis-related gene signature for prognostic prediction of patients with lung adenocarcinoma.
    Jin J; Liu C; Yu S; Cai L; Sitrakiniaina A; Gu R; Li W; Wu F; Xue X
    Aging (Albany NY); 2021 Jun; 13(12):16144-16164. PubMed ID: 34115610
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of critical ferroptosis regulators in lung adenocarcinoma that RRM2 facilitates tumor immune infiltration by inhibiting ferroptotic death.
    Tang B; Xu W; Wang Y; Zhu J; Wang H; Tu J; Weng Q; Kong C; Yang Y; Qiu R; Zhao Z; Xu M; Ji J
    Clin Immunol; 2021 Nov; 232():108872. PubMed ID: 34648954
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune landscape and a promising immune prognostic model associated with TP53 in early-stage lung adenocarcinoma.
    Wu C; Rao X; Lin W
    Cancer Med; 2021 Feb; 10(3):806-823. PubMed ID: 33314730
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SLC7A11 inhibits ferroptosis and downregulates PD-L1 levels in lung adenocarcinoma.
    Huang Z; Chen X; Wang Y; Yuan J; Li J; Hang W; Meng H
    Front Immunol; 2024; 15():1372215. PubMed ID: 38655266
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased expression of TTC21A in lung adenocarcinoma infers favorable prognosis and high immune infiltrating level.
    Wang W; Ren S; Wang Z; Zhang C; Huang J
    Int Immunopharmacol; 2020 Jan; 78():106077. PubMed ID: 31812070
    [TBL] [Abstract][Full Text] [Related]  

  • 12. GALNT2/14 overexpression correlate with prognosis and methylation: potential therapeutic targets for lung adenocarcinoma.
    Yu Y; Wang Z; Zheng Q; Li J
    Gene; 2021 Jul; 790():145689. PubMed ID: 33964375
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination of tumor mutation burden and immune infiltrates for the prognosis of lung adenocarcinoma.
    Zhao Z; He B; Cai Q; Zhang P; Peng X; Zhang Y; Xie H; Wang X
    Int Immunopharmacol; 2021 Sep; 98():107807. PubMed ID: 34175739
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictions of the dysregulated competing endogenous RNA signature involved in the progression of human lung adenocarcinoma.
    Yang D; He Y; Wu B; Liu R; Wang N; Wang T; Luo Y; Li Y; Liu Y
    Cancer Biomark; 2020; 29(3):399-416. PubMed ID: 32741804
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dysregulated ferroptosis-related genes indicate potential clinical benefits for anti-PD-1/PD-L1 immunotherapy in lung adenocarcinoma.
    Zhou M; Zhang X; Li T; Chen Y
    J Clin Lab Anal; 2021 Dec; 35(12):e24086. PubMed ID: 34752672
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synergistic Effects of Different Levels of Genomic Data for the Staging of Lung Adenocarcinoma: An Illustrative Study.
    Li Y; Mansmann U; Du S; Hornung R
    Genes (Basel); 2021 Nov; 12(12):. PubMed ID: 34946821
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comprehensive analysis of the autophagy-dependent ferroptosis-related gene FANCD2 in lung adenocarcinoma.
    Miao H; Ren Q; Li H; Zeng M; Chen D; Xu C; Chen Y; Wen Z
    BMC Cancer; 2022 Mar; 22(1):225. PubMed ID: 35236309
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protein phosphatase 1 regulatory subunit 3G (PPP1R3G) correlates with poor prognosis and immune infiltration in lung adenocarcinoma.
    Zhuo X; Chen L; Lai Z; Liu J; Li S; Hu A; Lin Y
    Bioengineered; 2021 Dec; 12(1):8336-8346. PubMed ID: 34592886
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Construction and analysis of a novel ferroptosis-related gene signature predicting prognosis in lung adenocarcinoma.
    Zhou J; Wang X; Li Z; Jiang R
    FEBS Open Bio; 2021 Nov; 11(11):3005-3018. PubMed ID: 34499810
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characteristic of molecular subtypes in lung adenocarcinoma based on m6A RNA methylation modification and immune microenvironment.
    Zhou H; Zheng M; Shi M; Wang J; Huang Z; Zhang H; Zhou Y; Shi J
    BMC Cancer; 2021 Aug; 21(1):938. PubMed ID: 34416861
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.